

TheMARK

GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes

DIABETES MANAGEMENT

Issue 16 - March 2019

Dear Healthcare Professionals,

In support of Diabetes Alert Day, GlycoMark is offering complementary educational materials for patients with diabetes!

1. The **NEW GlycoMark Patient Brochure** is a convenient tri-fold for patients to view in waiting or examination rooms. It is also a helpful guide for clinicians to review with patients. For a printer friendly version, [click here](#).
2. The **NEW GlycoMark Patient Brochure Table Display** serves as a poster or a table-top display that can also hold the GlycoMark Patient Brochures. Request a display for every area where your patients with diabetes can view.



Patients can now gain a better understanding of the importance of glucose control and learn how the GlycoMark test can help them take greater control of their diabetes.

These printed materials are available at www.glycomark.com/order-prints

Order Prints Now

How to Order the GlycoMark Test:

The GlycoMark test is reimbursed by most federal, state and private payers (CPT Code 84378) and available through various national and regional laboratories, and as a test kit for use on most automated chemistry instruments. [Click Here](#) for more information!

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not

intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2019 GlycoMark, Inc. All Rights Reserved. M-79-1A



805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com